Anti-Carbonyl Reductase 1 Antibody

The Antibodies.com polyclonal antibody targets Carbonyl Reductase 1 (CBR1), a cytosolic NADPH-dependent oxidoreductase belonging to the short-chain dehydrogenase/reductase superfamily. Produced in rabbit and supplied as an unconjugated whole antiserum in a 100 µL vial, the reagent is validated for Western blot, immunohistochemistry, and ELISA workflows against human samples. CBR1 catalyzes the reduction of a broad range of carbonyl substrates, including endogenous prostaglandins, lipid aldehydes formed during oxidative stress, and xenobiotic carbonyl-containing drugs, making the antibody useful for studies of carbonyl metabolism, cellular redox balance, and xenobiotic biotransformation. In cancer pharmacology, CBR1 contributes to the reductive metabolism of anthracyclines such as doxorubicin, so researchers studying cardiotoxicity, chemoresistance, and tissue-specific drug clearance frequently use anti-CBR1 reagents to profile enzyme expression across patient-derived or model-system tissues. The unconjugated format allows flexible pairing with reporter-conjugated secondary antibodies suited to individual detection chemistries.